Home > Products > Hemoglobin Removal Kits >

NuGel-HemogloBind™ - Hemoglobin Capture Reagent From Blood and Hemolyzed Serum

NuGel-HemogloBind™ - Hemoglobin Capture Reagent From Blood and Hemolyzed Serum


Base Price: $585.00

Product Code: NP-HO

Size (NP-HO):


Hemoglobin Capture Reagent From Blood and Hemolyzed Serum with NuGel™ Matrix

  • Has a high degree of specificity for hemoglobin binding up to 10 mg/ml
  • Removes hemoglobin from any species including human, mouse, rat, sheep, bovine, goat, etc
  • Removes hemoglobin from organs, tissues.
  • Hemoglobin removal from red blood cell lysate for proteomics and biomarker drug discovery
  • The flow through fractions(hemoglobin depleted) retain their enzymatic and biological activity
  • The flow through fractions(hemoglobin depleted) is compatible with LC-MS, activity based protein profiling and proteomic studies.
  • Linearly scaleable up or down. Easy high throughput automation.

NuGel-Hemoglobind™ is reengineered for increased stability. It is based on NuGel silica (50 microns in size, 1000Å) covalently bound to elastomeric polyelectrolytes. It binds >95% of hemoglobin from blood.

Click Here To View NuGel-Hemoglobind™ Product Sheet

Related HemogloBind™ References

Biological Fluids
J Krupey - United States Patent: 10/180,053, 2002 Removal of extraneous substances from biological fluids containing nucleic acids and the recovery of nucleic acids

Red Cell Lysates
Kyoungsook Park, Christopher D. Saudek, and Gerald W. Hart Increased Expression of β-N-Acetylglucosamindase (O-GlcNAcase) in Erythrocytes from Prediabetic and Diabetic Individuals.Diabetes.2010;59(7):1845-50.

Stored Blood Products
Delobel J., Rubin O., Prudent M., Crettaz D., Tissot J.-D., Lion N.(2010) Biomarker Analysis of Stored Blood Products: Emphasis on Pre-Analytical Issues. International Journal of Molecular Sciences. 11(11):4601-4617

Red Blood Cells
Alvarez-Llamas, Gloria, Fernando de la Cuesta, Maria G. Barderas, Irene Zubiri, Maria Posada-Ayala, and Fernando Vivanco. "Characterization of Membrane and Cytosolic Proteins of Erythrocytes." In Vascular Proteomics, pp. 71-80. Humana Press, 2013

Alvarez-Llamas, G., de la Cuesta, F., Barderas, M. G., Darde, V. M., Zubiri, I., Caramelo, C., Vivanco, F. A novel methodology for the analysis of membrane and cytosolic sub-proteomes of erythrocytes by 2-DE.Electrophoresis.2009;30:4095-4108

Zihao Wang, Kyoungsook Park, Frank Comer1, Linda C. Hsieh-Wilson, Christopher D. Saudek, Gerald W. Hart. Site-Specific GlcNAcylation of Human Erythrocyte Proteins: Potential Biomarker(s) for Diabetes Mellitus. Diabetes.2008;58, 309-317.

Datta, Pradip. Effect of Hemolysis, High Bilirubin, Lipemia, Paraproteins, and System Factors on Therapeutic Drug Monitoring. Handbook of Drug Monitoring Methods.2008; 97-109.

Yuichi Miki, Tomoki Tazawa, Kazuya Hirano, Hideki Matsushima, Shoko Kumamoto, Naotaka Hamasaki, Tomohiro Yamaguchi, Masatoshi Beppu. Clearance of oxidized erythrocytes by macrophages: Involvement of caspases in the generation of clearance signal at band 3 glycoprotein. Biochemical and Biophysical Research Communications.2007; 363(1):57-62

Sarawathi,et al., Relative quantification of glycated Cu-Zn superoxide dismutase in erythrocytes by electrospray ionization mass spectrometry, Biochimica et Biophysica Acta. 1999.1426(3):483-90

Person, N.B., Effect Of HemogloBind™ On Interference Reduction In Bilirubin Analysis.poster Clinichem, 1995.

Baion, C.M. & Ali, A.C.Evaluation Of HemogloBind™ For Removal Of O-Raffinose Crosslinked Hemoglobin (Hemolink™) From Serum, poster AACC Meeting 1997.

Padilla, S., Convenient Method for Decreasing the Amount of Hemoglobin in Tissue Samples Without Affecting the Level of Cholinesterase Activity, unpublished personal correspondence, 1994.